advanced or metastatic extrapulmonary neuroendocrine carcinoma research hub

A Phase III, multi-center, open-label, randomised, controlled trial of intravenous obrixtamig in combination with carboplatin and etoposide vs. carboplatin and etoposide as first-line therapy in DLL3-positive patients with unresectable locally advanced or metastatic extrapulmonary neuroendocrine carcinomas.

This study looks at a new drug (obrixtamig) alongside standard chemotherapy for certain advanced or spread neuroendocrine cancers, aiming to improve survival. Participants receive either the new combination or chemotherapy alone.